Genscript Biotech Corporation Sustainability Profile
Genscript Biotech Corporation, a leading player in the biotechnology industry, is headquartered in China (CN) and operates extensively across North America, Europe, and Asia. Founded in 2002, Genscript has established itself as a pioneer in gene synthesis, peptide synthesis, and antibody development, catering to a diverse range of sectors including pharmaceuticals, diagnostics, and academic research. The company’s core offerings, such as its innovative gene editing tools and custom protein services, are distinguished by their high quality and rapid turnaround times. Genscript's commitment to advancing life sciences has earned it a prominent market position, with notable achievements including numerous collaborations with top-tier research institutions and a robust portfolio of intellectual property. As a trusted partner in biotechnological advancements, Genscript continues to drive innovation and support scientific discovery globally.
DitchCarbon Score
How does Genscript Biotech Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genscript Biotech Corporation's score of 57 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genscript Biotech Corporation's reported carbon emissions
In 2024, Genscript Biotech Corporation reported total greenhouse gas emissions of approximately 39376800 kg CO2e for Scope 1, 114034820 kg CO2e for Scope 2 (market-based), and 387589810 kg CO2e for Scope 3 emissions. This reflects a significant commitment to reducing their carbon footprint, with a total of about 153411610 kg CO2e for combined Scope 1 and 2 emissions (market-based). Genscript has set ambitious reduction targets as part of its climate commitments. The company aims to achieve a 54.6% reduction in absolute Scope 1 and 2 emissions by 2033, using 2023 as the base year. Additionally, they plan to reduce Scope 3 emissions by 32.5% within the same timeframe. Long-term goals include a 90% reduction in both Scope 1 and 2 emissions by 2050, as well as a 90% reduction in Scope 3 emissions. Furthermore, Genscript is committed to ensuring that 83% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2029. The company has pledged to reach net-zero greenhouse gas emissions across its value chain by 2050, aligning with industry standards for climate action. This data is sourced directly from Genscript Biotech Corporation, with no cascading from a parent organization.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 48,821,780 | 00,000,000 |
| Scope 2 | 83,758,360 | 000,000,000 |
| Scope 3 | 314,658,760 | 000,000,000 |
How Carbon Intensive is Genscript Biotech Corporation's Industry?
How Carbon Intensive is Genscript Biotech Corporation's Location?
Genscript Biotech Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genscript Biotech Corporation has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
